<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336550">
  <stage>Registered</stage>
  <submitdate>23/02/2011</submitdate>
  <approvaldate>28/02/2011</approvaldate>
  <actrnumber>ACTRN12611000217909</actrnumber>
  <trial_identification>
    <studytitle>Diabetes and antenatal milk expressing (DAME) : a randomised controlled trial.</studytitle>
    <scientifictitle>Investigation of the effect of antenatal milk expressing on babies of women with diabetes in pregnancy compared to the outcomes of babies of women with diabetes in pregnancy receiving standard care</scientifictitle>
    <utrn>U1111-1119-4839</utrn>
    <trialacronym>DAME</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neonatal admission to Special and Intensive care, ,</healthcondition>
    <healthcondition>Neonatal/infant feeding</healthcondition>
    <healthcondition>Hypoglycaemia</healthcondition>
    <healthcondition>Lactation</healthcondition>
    <healthcondition>Pregnancy outcomes</healthcondition>
    <healthcondition>Maternal diabetes,</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Women with diabetes in pregnancy who are intending to breastfeed will commence twice daily antenatal milk expressing from 36 weeks gestation until birth.</interventions>
    <comparator>Women with diabetes in pregnancy who are intending to breastfeed will receive usual care. In usual care women are not advised to commence expressing breast milk antenatally.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish whether the practice of antenatal breast milk expressing from 36 weeks gestation for women with diabetes in pregnancy increases the proportion of infants who require admission to the special or intensive care nursery compared with infants of women with diabetes in pregnancy receiving standard care (30% vs 20%).</outcome>
      <timepoint>Admission during the hospital stay following birth - data from medical record</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To establish whether the practice of antenatal breast milk expressing from 36 weeks gestation for women with diabetes in pregnancy increases the proportion of of infants receiving exclusive breast milk at three months of age compared with infants of women with diabetes in pregnancy receiving standard care (52% vs 40%).</outcome>
      <timepoint>Three months postpartum by telephone interview</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish whether the practice of antenatal breast milk expressing from 36 weeks gestation for women with diabetes in pregnancy increases the proportion of of infants receiving exclusive breast milk during the hospital stay after birth compared with infants of women with diabetes in pregnancy receiving standard care (37% vs 25%).</outcome>
      <timepoint>Admission during the hospital stay following birth - data from medical record</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish whether the practice of antenatal breast milk expressing from 36 weeks gestation for women with diabetes in pregnancy decreases the mean gestation at birth compared with infants of women with diabetes in pregnancy  receiving standard care (37 weeks vs 38 weeks).</outcome>
      <timepoint>Collected from the medical record following birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any woman with pre-existing or gestational diabetes; between 34 and 36 weeks gestation; with a singleton pregnancy in a cephalic presentation; attending the study sites for pregnancy care as a public patient; planning to breastfeed and able to speak , read and write in English</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women -any history of antepartum haemorrhage, or placenta praevia -an unknown or classical caesarean section scar or more than one lower uterine segment caesarean section scar -any suspicion of fetal compromise - a known fetal abnormality.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Computerised random number generator will be accessed by computer to ascertain the woman's allocation</concealment>
    <sequence>Random permutated blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Data abstarction for the primary outcome will be blinded to group allocation. Medical records which will be seen by care providers will note study participation but not trial arm. Women (participants) can not be blinded to allocation.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2011</anticipatedstartdate>
    <actualstartdate>6/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>23/10/2015</actualenddate>
    <samplesize>658</samplesize>
    <actualsamplesize>635</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Women's Hospital - Parkville</hospital>
    <hospital>Mercy Hospital for Women - Heidelberg</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>3199 - Frankston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Judith Lumley Centre, La Trobe University</primarysponsorname>
    <primarysponsoraddress>215 Franklin St, 
Melbourne, 
Victoria. 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council, Australia</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Women's Hospital</sponsorname>
      <sponsoraddress>Locked bag 300, 
Parkville, 
Victoria. 3052</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Mercy Hospital for Women</sponsorname>
      <sponsoraddress>163 Studley Rd 
Heidelberg, 
Victoria. 3084</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Monash Medical Centre, Southern Health</sponsorname>
      <sponsoraddress>246 Clayton Road
Clayton VIC 3168</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Infants of women with diabetes in pregnancy have an increased risk of low blood sugar and other complications after birth and of  developing diabetes and being obese later in life. Many maternity providers encourage these women to express breast milk before birth to have it  available if the infant needs supplementary feeding. 

Evidence for this practice is lacking so we are planning the first study exploring the safety and effectiveness of antenatal expression of breast milk in late pregnancy for women with diabetes in pregnancy.</summary>
    <trialwebsite />
    <publication>Forster DA, Jacobs S, Amir LH, et al. Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised
controlled trial. BMJ Open 2014;4:e006571.
doi:10.1136/bmjopen-2014-006571

Forster DA,  Moorhead AM,  Jacobs SE, ... Amir LH.   Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial.
The Lancet. 2017 Jun 3;389(10085):2204-2213. doi: 10.1016/S0140-6736(17)31373-9
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mercy Hospital For Women</ethicname>
      <ethicaddress>163 Studley Rd
Heidelberg, 
Victoria. 3084</ethicaddress>
      <ethicapprovaldate>8/03/2011</ethicapprovaldate>
      <hrec>MHW HREC ID number 11/06</hrec>
      <ethicsubmitdate>19/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Womens Hospital</ethicname>
      <ethicaddress>Locked bag 300,
Parkville,
Victoria. 3052</ethicaddress>
      <ethicapprovaldate>23/03/2011</ethicapprovaldate>
      <hrec>RWH HREC  ID number 11/07</hrec>
      <ethicsubmitdate>17/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>La Trobe University Human Ethics Committee</ethicname>
      <ethicaddress>La Trobe University
Bundoora
Victoria. 3086</ethicaddress>
      <ethicapprovaldate>31/03/2011</ethicapprovaldate>
      <hrec>La Trobe University Human Ethics Application No. 11-004</hrec>
      <ethicsubmitdate>19/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Health HREC</ethicname>
      <ethicaddress>246 Clayton Road
Clayton VIC 3168
.</ethicaddress>
      <ethicapprovaldate>13/07/2012</ethicapprovaldate>
      <hrec>MMC 12181-B</hrec>
      <ethicsubmitdate>5/06/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Barwon Health </ethicname>
      <ethicaddress>Corporate Office
Ryrie St
Geelong
Victoria 3220</ethicaddress>
      <ethicapprovaldate>26/03/2013</ethicapprovaldate>
      <hrec>BH 13/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peninsula Health Human Resaerch Ethics Committee</ethicname>
      <ethicaddress>PO Box 192 Mount Eliza, Victoria. 3930</ethicaddress>
      <ethicapprovaldate>10/07/2014</ethicapprovaldate>
      <hrec>HREC/14/PH/21</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Della Forster </name>
      <address>Judith Lumley Centre,  La Trobe University 215 Franklin St Melbourne Victoria 3000</address>
      <phone>+61 39479 8783</phone>
      <fax />
      <email>d.forster@latrobe.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Anita Moorhead</name>
      <address>Judith Lumley Centre,  La Trobe University 215 Franklin St Melbourne Victoria 3000</address>
      <phone>+ 61 3 8345 2932</phone>
      <fax />
      <email>dame@latrobe.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anita Moorhead</name>
      <address>Judith Lumley Centre,  La Trobe University 215 Franklin St Melbourne Victoria 3000</address>
      <phone>+61 3 8345 2932 </phone>
      <fax />
      <email>a.moorhead@latrobe.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Della Forster </name>
      <address>Judith Lumley Centre,  La Trobe University 215 Franklin St Melbourne Victoria 3000</address>
      <phone>+61 3 9479 8783</phone>
      <fax />
      <email>d.forster@latrobe.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>